Please ensure Javascript is enabled for purposes of website accessibility

1 Big Problem in Johnson & Johnson's Latest Earnings Call

By Cory Renauer - Feb 7, 2021 at 8:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus pandemic continues to pressure one of the company's big operating segments.

Johnson & Johnson (JNJ 0.70%) pleased investors with a fourth-quarter earnings call that was generally positive. Unfortunately, the coronavirus pandemic continues to pressure one of the company's big operating segments.

In this Motley Fool Live video, recorded on Jan. 29, healthcare and cannabis bureau chief Corinne Cardina and writer Cory Renauer discuss the big problem facing Johnson & Johnson's medical device segment.

Corinne Cardina: Is there anything that raised eyebrows in Johnson & Johnson's earnings that might be a red or yellow flag.

Cory Renauer: I wouldn't call it a red flag, I'd call it yellow. The company's medical device segment has not been doing well during the coronavirus pandemic. It's hard to say when it's going to bounce back, it might be the first quarter or second quarter or the third. That's because a lot of the company's medical device segment is comprised of hip and knee replacements, which when you need one you one. But you can generally put it off until there isn't a pandemic going on. So that's not a red flag, yellow flag, and something that will probably work itself out.

Cardina: Right. That's a similar tailwind to what will discuss with Intuitive Surgical in a few minutes. Overall, would you say that Johnson & Johnson is a buy?

Renauer: Overall, yes. Johnson & Johnson has been a good stock to buy for over a century. That said, it is a little bit expensive now and you might have to hang on for a long time before you see a positive return if the market goes south next month. But if you hang onto it long enough you will probably come out ahead. This is a good safe stock to buy, it makes a good cornerstone for any portfolio.

Cardina: Certainly. Of course, it has a nice dividend. So the dividend yields about 2.4%. It is a very large company. So like you said, this isn't something that is going to double or triple in the next year. But it is certainly could be a strong component to a diversified portfolio. Johnson & Johnson is in itself very diversified. We mentioned those segments. The pharmaceuticals really boosted it when its medical devices were not doing so well. Its consumer segment has not done terribly during the pandemic.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$178.08 (0.70%) $1.23
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$219.53 (-1.86%) $-4.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.